CD8A and neoplasm: Together with additional in vivo and in vitro studies, the results reveal that TNIKi treatment can trigger potent CD8+ T cell-mediated antitumor responses by inducing immunogenic tumor cell death,[9] further promoting CD8+ T cell recruitment.